Macular Degeneration: Risk Factors and the Self-Checks Worth Doing

Age-related macular degeneration has four risk factors the National Eye Institute names outright: age, especially 55 and older; a family history of AMD; being Caucasian; and smoking. Only the last one is yours to change. The American Academy of Ophthalmology's list adds high blood pressure, being overweight, a diet high in saturated fat, heart disease and high cholesterol.

So the risk picture sorts into two piles, and the sorting is the useful part. One tells you how closely to watch. The other tells you what to do this year. Both matter more than usual here, because AMD's defining feature is that noticing is exactly what does not happen — the NEI says early dry AMD causes no symptoms at all. For the wider view, see our guide to eye health after 50. This piece is AMD specifically: the risk factors, the two self-checks worth doing, and the one supplement claim the market has inverted.

We are a research desk, not a clinic, and we did not examine anyone. Every figure below is attributed to its source.

What the macula is, and why a few millimeters decide so much

The macula is the small central patch of retina that handles sharp, detailed vision — reading, faces, road signs, the number on a pill bottle. A tiny fraction of the retina does almost all the work you consciously notice.

That is why damage there is so disproportionate. According to the American Academy of Ophthalmology, AMD "causes loss of central vision but does not affect side vision." People with advanced AMD usually keep enough peripheral vision to cross a room, and lose the part of sight that reads a menu. It is common, too: the National Eye Institute says 11 million people in the United States have AMD, and calls it a leading cause of vision loss in older adults.

Macular degeneration risk factors you cannot change

These give you nothing to do. They tell you how seriously to take the monitoring.

• Age. The National Eye Institute puts it simply: "People age 55 and older are more likely to have AMD."
• Family history of AMD. Listed by both the NEI and the AAO. If a parent or sibling has been diagnosed, say so at your next exam.
• Ancestry. The NEI lists "are Caucasian" among the groups at higher risk; the AAO's patient page says "White people also have an elevated risk of getting AMD." We report it as the factor those bodies list.
• Genetics, interacting with habits. An NEI-funded study of women found that a genetic predisposition for AMD significantly increased the odds of developing it when combined with heavy smoking plus little exercise or low fruit and vegetable intake.

One item you will meet in consumer material: light-colored irises. Neither the NEI's list nor the AAO's includes iris color, so we are not handing it to you as a risk factor.

Macular degeneration risk factors you can change, starting with the one that matters most

Smoking is not one modifiable risk factor among several. It is the one with real magnitude behind it.

A study by Khan and colleagues in the British Journal of Ophthalmology in 2006 measured risk against pack-years rather than a yes-or-no smoking question. For people with more than 40 pack-years, the odds ratio for AMD was 2.75 (95% CI 1.22 to 6.20) compared with non-smokers — 3.43 (95% CI 1.28 to 9.20) for geographic atrophy and 2.49 (95% CI 1.06 to 5.82) for choroidal neovascularisation, the two forms of advanced disease. The authors reported "a strong association between the risk of both GA and CNV and pack years of cigarette smoking."

The useful half of that finding concerns former smokers: the same study reported that risk in people who had not smoked for over 20 years was comparable to non-smokers. Quitting is not a gesture here.

The rest of the modifiable list comes from the AAO's patient page: a diet high in saturated fat, being overweight, high blood pressure, heart disease and high cholesterol. Those are cardiology's levers, which is less of a coincidence than it sounds — the macula depends on a dense, fragile blood supply.

On diet, the evidence is suggestive rather than settled. A 2024 systematic review and meta-analysis in the Tzu Chi Medical Journal pooled seven studies and found medium-to-high adherence to a Mediterranean-style diet associated with a lower risk of developing AMD (hazard ratio 0.82, 95% CI 0.75 to 0.90), and medium adherence associated with a lower risk of progression to advanced AMD (hazard ratio 0.87, 95% CI 0.81 to 0.93), while flagging considerable heterogeneity that "warrants cautious interpretation." Observational data: association, not cause. Sunglasses come up constantly in prevention advice; we found no estimate of comparable quality, so wear them for glare.

Dry AMD versus wet AMD, and why the difference changes what you watch for

This pair is routinely described as mild and severe. That is wrong, and getting it right is most of the clinical literacy the topic requires.

• Dry AMD is the common form. The American Academy of Ophthalmology states that "about 80 percent (8 out of 10) of people who have AMD have the dry form," describing it as parts of the macula getting thinner with age, with tiny deposits called drusen building up.
• Wet AMD is less common and faster. The AAO describes new, abnormal blood vessels growing under the retina, which may leak, with vision loss faster than in dry AMD. The NEI calls wet AMD "a less common type of late AMD that usually causes faster vision loss."
• Wet AMD is a late stage, not a separate disease. The NEI's framing places it inside late AMD, which means dry AMD is not the harmless version — it is the stage where there is still something to monitor.

Treatment follows the same split. For wet AMD, the AAO describes anti-VEGF medications as a class that helps reduce leaking from abnormal blood vessels in the retina, delivered into the eye through a very thin needle. A retina specialist decides whether that applies. For dry AMD, nothing restores vision already lost; everything available is about slowing what comes next. That is why the self-checks below exist.

Early signs of macular degeneration, stage by stage

The National Eye Institute stages dry AMD in three steps, and the symptom list for the first one is empty.

• Early dry AMD. The NEI is unambiguous: "Early dry AMD doesn't cause any symptoms."
• Intermediate dry AMD. Some people still have none. Others, per the NEI, may notice "mild blurriness in their central vision or trouble seeing in low lighting."
• Late AMD, wet or dry. The NEI says straight lines start to look wavy or crooked, and a blurry area appears near the center of vision that may grow larger or develop blank spots.

Read that sequence twice. By the time the disease announces itself in a way you cannot miss, it is late-stage. The NEI's instruction follows: "Early AMD doesn't have any symptoms, so don't wait for your vision to change!" The AAO notes the same thing from the other side — many people do not realize they have AMD until their vision is very blurry.

The middle stage has a complication. Mild central blurriness and trouble in low light are also features of ordinary aging — several common vision changes after 50 produce exactly those complaints. You cannot sort that out yourself. What you can do is notice the change rather than adjust to it.

The Amsler grid, done properly

The Amsler grid is a square of fine graph-paper lines with one dot in the center — a change detector for distortion in central vision. The AAO recommends daily use for people who have AMD, and publishes the grid and its instructions free.

Its instructions, followed exactly:

• Wear any glasses you normally use to read. The test runs at reading distance, so that correction belongs on your face.
• Hold the grid 12 to 15 inches away, in good light. Same distance, same light, every time — otherwise you are measuring the room.
• Cover one eye. One at a time is the point: with both eyes open, your brain fills in for the weaker one and a real change can hide for months.
• Look directly at the center dot and keep your eye focused on it. The test happens in your peripheral awareness while you stare. Letting your gaze wander defeats it.
• Check for any lines or areas that look blurry, wavy, dark or blank.
• Repeat with the other eye, then again tomorrow. The AAO's guidance is once a day, every day.

If any part of the grid looks darker, wavy, blank or blurry, the AAO says to contact your ophthalmologist right away. The point of the daily habit is that a change becomes a call you make this morning rather than something you notice next spring. Our guide on how to test your vision at home takes the protocol further.

What the Amsler grid misses

Here is where we part company with the way the grid is usually sold.

A systematic review and meta-analysis by Bjerager and colleagues, published in JAMA Ophthalmology in April 2023, pooled 10 studies covering 1,890 eyes. Against healthy controls, the grid identified neovascular AMD with 67% sensitivity and 99% specificity. For the harder and more clinically relevant job — separating neovascular from non-neovascular AMD — sensitivity was 71% and specificity 63%. The authors concluded that the grid "may not have adequate sensitivity or specificity to make it a reliable tool for at-home monitoring."

The AAO's commentary on that review drew the practical conclusion: patients with non-neovascular AMD should undergo regular eye examinations regardless of the results of an Amsler grid test. The included studies also ran the test in clinics under supervision rather than at home, which if anything flatters the home-use case.

So the honest framing is narrow. The grid is a monitoring tool for people with known AMD or known elevated risk, not a screening test for the general public, and a clean grid is not evidence that your retina is fine.

The change that warrants a same-week call

One symptom outranks the rest: straight lines that suddenly look wavy, crooked or broken, or a new blurry or blank patch near the center of your vision. The National Eye Institute calls wavy straight lines a warning sign for late AMD and says to see your eye doctor right away.

Do not spend a week deciding whether it is real. Central distortion has several possible causes, some treatable and time-sensitive, and telling them apart takes equipment you do not own. Describing the change accurately — which eye, when, whether it is growing — is your job. Naming it is theirs.

Do supplements for macular degeneration help?

Yes, but only for people who already have intermediate AMD, or advanced AMD in one eye. No, as prevention — and no benefit was shown for early AMD either. The gap between those answers is where a large retail category lives.

Start with the trial. According to the National Eye Institute, AREDS2 "included only people with intermediate AMD in both eyes or intermediate AMD in one eye and advanced AMD in the other eye" and excluded people without AMD or with early AMD — the latter, in the NEI's words, "because AREDS data showed no benefit for these individuals." The NEI states flatly that AREDS and AREDS2 supplements "do not prevent AMD onset."

Where there is a number, it is a real one. The NEI reports that the formulation reduces the risk of progression from intermediate to advanced AMD by about 25 percent, and its patient page describes the eligible situations: with intermediate AMD in one or both eyes, these supplements may be able to stop it from turning into late AMD; with late AMD in only one eye, they may slow AMD in the other eye. Note the verb throughout. It slows progression. It does not restore vision, sharpen normal vision, or reduce anyone's need for glasses.

The beta-carotene story explains why the formula changed, and it is the most useful fact here. The original AREDS formula contained beta-carotene; AREDS2 tested removing it, because beta-carotene, in the NEI's words, "in some studies increased lung cancer risk in smokers." The National Cancer Institute's PDQ summary gives the figure from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention trial in male smokers: higher lung cancer incidence with beta-carotene, relative risk 1.18, 95% CI 1.03 to 1.36 — an 18% increase. Lutein and zeaxanthin took its place, and the NEI advises that current and former smokers should take the AREDS2 formula. Composition details live in our piece on the AREDS2 and AREDS3 formulas.

For everyone whose last exam was clean, the Cochrane evidence is the one to read. The 2017 review by Evans and Lawrenson, CD000253, pooled five randomised controlled trials with data on 76,756 people and concluded: "Taking vitamin E or beta-carotene supplements will not prevent or delay the onset of AMD." The authors wrote that the same probably applies to vitamin C and the one multivitamin tested so far. Their closing caution deserves quoting rather than paraphrase: "Although generally regarded as safe, vitamin supplements may have harmful effects, and clear evidence of benefit is needed before they can be recommended."

Our read, the same one we reach on whether eye vitamins work: with a diagnosis of intermediate AMD, or advanced AMD in one eye, this is one of the few supplement categories in the aisle with a trial-grade number attached. Without one, an eye-health bottle is an expensive multivitamin with a picture of an eye on it. A diagnosis makes the formula relevant. Packaging does not.

What the exam finds, and how often to have one

The self-checks detect change. The exam detects disease, and it does so before you can feel anything.

According to the National Eye Institute, eye doctors check for AMD during a dilated eye exam, and may also use optical coherence tomography to image the layers of the retina. Drusen and early thinning show up there while your vision still feels normal. No home test reaches that.

On interval: the AAO's 2025 Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern sets the recommended frequency for adults 65 and older without eye-disease risk factors at every one to two years, and increased frequency for adults who do have risk factors. The NEI's advice is more personal and equally sound — ask your doctor how often you need exams. If AMD runs in your family, or you have smoked heavily, that is a conversation rather than a number off a chart. See our guide to how often to get an eye exam.

What we would actually do

Stop smoking, or stay stopped — it is the only risk factor on the NEI's list you control, and the pack-year data suggests the benefit accrues over years. Treat blood pressure and cholesterol as eye care, because the AAO lists both. Keep the exam interval your eye doctor sets, dilation included. If you have AMD, run the Amsler grid daily at 12 to 15 inches with your reading glasses on, and call the same week if a line bends. If you do not, skip the supplement and raise your family history at your next exam.

The rest is patience with a disease that gives no early warning. That is not a reason for anxiety. It is a reason to keep the appointment you would otherwise push to next year — and to read our complete guide to eye health after 50 for how AMD fits alongside the dry eye, cataract and night-vision changes that arrive at the same time.